HGSI: This can perhaps be construed as good news for investors insofar as NVS/HGSI presumably won’t waste any more money on the Albuferon program. Albuferon wasn’t going to be a commercial success in any case.
Although the BLA with the FDA is still pending, I’m taking the liberty of moving Albuferon from paragraph #2 to paragraph #6 (back-burner programs) in the next revision of “HCV: Most Likely to Succeed.”
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.